Pankaj Kumar

Pankaj Kumar

Auto-generated profile, based on publicly available information

Pankaj Kumar

All India Institute of Medical Sciences, New Delhi, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Cancer Biomarkers
Verified
Journal Article
Open access
CHChing-Wen Hou
Ching-Wen Hou
PKPankaj Kumar
Pankaj Kumar
SWStacy Williams
Stacy Williams
MZMeilin Zhu
Meilin Zhu
UOUwa Obahiagbon
Uwa Obahiagbon
KAKaren S. Anderson
Karen S. Anderson
Background: Among head and neck squamous cell carcinomas (HNSCCs), the incidence of oropharyngeal cancer (OPC) has been increasing in recent decades. Human papillomavirus (HPV) type 16 is associated with the majority of OPC. Circulating antibodies (Abs) to multiple HPV16 early antigens, including E2, E6, and E7, have been detected in patient sera, and are strongly associated with risk for OPC. However, HPV serology currently requires laboratory-based tests that are difficult to implement for large-scale cancer screening. Objective: The goal of this study was to develop and validate a point-of-care assay for rapid detection of circulating IgG to HPV16 early antigens. Methods: We measured Abs to HPV16 E2, E6, and E7 proteins using a lateral flow assay (LFA) in sera from 119 newly diagnosed OPC cases, 41 partners, and 81 healthy volunteers. The 119 patients with HPV-OPC were classified as HPV-positive based on in situ hybridization (ISH) or institutional p16 immunohistochemistry. The sensitivity and specificity of the LFA were determined by comparing to clinical diagnosis. Results: The specificity for each individual HPV16 E2, E6, and E7 antibodies was 95.1% (77/81), 96.3% (78/81), and 98.7% (80/81), respectively. The sensitivities of the individual HPV16 antibodies were as follows: E2, 47.9% (57/119), E6, 31.9% (38/119), and E7, 57.1% (68/119). The 3-biomarker panel (at least one positive for E2, E6, and E7 Abs) demonstrated a sensitivity of 76.5% (91/119) and a specificity of 92.6% (75/81). Conclusions: We developed a multiplexed lateral flow assay for the rapid detection of serologic responses to HPV16. Further research is required to determine the utility of these tests for HPV + HNSCC cancer screening, as higher specificity, and an assessment of the benefits of positive test results have yet to be evaluated in this context.

1 October 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
VNVi T. Nguyen
Vi T. Nguyen
SASiril Arockiam
Siril Arockiam
PKPankaj Kumar
Pankaj Kumar
JEJoshua Eger
Joshua Eger
KHKirk Herman
Kirk Herman
JCJennifer Blain Christen
Jennifer Blain Christen
PURPOSE: Translation of diagnostic technology developed at the laboratory bench involves iterations of user feedback and design modifications. Learning about translational requirements early in the design process facilitates the development of feasible prototypes that have a better likelihood of implementation in global health settings. During our development of a portable system to detect human papillomavirus (HPV) for cervical cancer screening in India, we encountered and solved issues related to research translation. We report our findings to help others deploying diagnostic technology for global health. MATERIALS AND METHODS: We designed a point-of-care system to process patient samples and diagnose HPV infection in the cervix. We continually shipped components of the system from the United States to our collaborating team in India to assess component condition and usability at the local site. We simultaneously developed HPV isothermal amplification assays that were fit for purpose. Cervical brush samples were used in our portable system for functional validation. RESULTS: We found ideal transport methods to ensure component quality and reagent stability through the international shipment chain. Portable systems should be designed as simple as possible for correct usage at the local testing site. Usability tests drove our design improvements from 28% to 93% success rates. We demonstrated proof-of-concept functionality of our portable system for 13 cervical brush samples on-site, with a sensitivity of 100% and specificity of 88.9%. CONCLUSION: Issues related to technology transfer for global health settings manifest during distribution and deployment of prototypes. We identified several issues during our synergistic design process and report recommendations on the basis of our experience.